AMI’s policy team is one of the most active in the sector - read the latest news here.
The AMR Accelerator projects have called for long-term investments, stressing the need to preserve the European capacity for antibiotic R&D by sustaining the assets, expertise, and research infrastructures required to develop new treatments for drug-resistant infections.